Skip to content
Parakho

Q1 FY27, unaudited

Revenue
₹764.40 Cr
Profit after tax
₹165.90 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations764.40+19.31%2,647.60
Other income29.90+13.69%112.70
Total income794.30+19.09%2,760.30
Employee benefit expense125.00−0.64%475.20
Finance costs6.10+35.56%22.00
Depreciation & amortisation40.00+21.95%154.10
Total expenses572.00+15.65%2,070.00
Profit before tax222.30+28.94%660.20
Tax expense56.40+30.86%152.00
Profit after tax165.90+28.31%508.20
Total comprehensive income167.20+30.22%513.20
Earnings per share
Earnings per share, basic₹9.94₹30.45
Earnings per share, diluted₹9.92₹30.40

Q1 FY27 unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base unaudited, from the company’s filing with NSE. Source

FY26 from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Dr Lal PathLabs reported Q1 FY27 revenue of Rs. 798 crore, up 19.1% year-on-year, driven by patient volume growth of 8.2% and sample volume growth of 10.7%. EBITDA rose 28.7% to Rs. 247 crore with a margin of 31.0%, while profit after tax grew 27.2% to Rs. 170 crore. Management attributed part of the realization growth to CGHS/ECHS price increases and discussed rural outreach expansion, international ventures in Dubai and Ghana, and continued investment in scientific and digital initiatives.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 53 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 19 Aug 2026.